Recombinant Anti-CD317 x Anti-CD16 Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD317 antibody variable domain is fused to the C terminal of an IgG of anti-CD16 antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Multiple myeloma (MM) therapy.